Search Results - craig+thomas

10 Results Sort By:
BODIPY-FL Nilotinib (Tasigna) for Use in Cancer Research
Abstract: The National Cancer Institute''s Laboratory of Cell Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize bodipy conjugated tyrosine kinase inhibitors that are currently used in the clinic for the treatment of CML or gastric cancers. We are also...
Published: 10/28/2024   |   Inventor(s): Suneet Shukla, Amanda Skoumbourdis, Craig Thomas, Suresh Ambudkar
Keywords(s): BODIPY-FL, nilotinib, Tasigna, Tyrosine Kinase Inhibitor (TKI)
Category(s): Application > Research Materials, Collaboration Sought > Licensing, TherapeuticArea > Oncology
Anti-Viral Compounds that Inhibit HIV Activity
Abstract: Several novel tropolone derivatives have been identified that inhibit HIV-1 RNase H function and have potential for anti-viral activity due to reduced cellular toxicity.  Inhibiting RNase H function is a potential treatment for many viral infections, since RNase H function is essential for viral replication for many pathogenic retroviruses...
Published: 4/8/2024   |   Inventor(s): John Beutler, Jian-kang Jiang, Suhman Chung, Craig Thomas, Stuart LeGrice, Jennifer Wilson
Keywords(s): AIDS, HIV, ribonuclease H, RNase H, tropolone derivative, viral replication
Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease
Development and Use of O-linked beta-N-acetylglucosamine (O-GlcNAc) Transferase (OGT) Inhibitors for Multiple Conditions, Including Cancer
This technology includes the development and use of small molecules that inhibit O-linked beta-N-acetylglucosamine (O-GlcNAc) transferase (OGT) for a variety of pathologies, including Alzheimer's disease, cancer, cancer, diabetes, and neurodegenerative disorders the treatment of cancer and as a potential antiviral. OGT is a ubiquitous enzyme that catalyzes...
Published: 10/28/2024   |   Inventor(s): Sara Martin Schwanger, Craig Thomas, Damien Duveau, Suzanne Walker
Keywords(s): 0-GlcNAc, Development, Developmtent, Inhibitors, OGT, THEREOF, TRANSFERASE, USES, VEXXXX, WIXXXX, WKXXXX
Category(s): Application > Research Materials, TherapeuticArea > Neurology, Application > Therapeutics
Treatment of Acute Myeloid Leukemia (AML) with the Multi-kinase FLT3-IRAK1/4 Inhibitor, NCGC1481, to Avoid Adaptive Resistance
This technology includes the identification and use of a novel small molecule, NCGC1481, to inhibit both the FLT3 and IRAK1/4 kinase pathways for treating acute myeloid leukemia (AML). An activating mutation of the FMS-like receptor kinase 3 (FMT3) occurs in approximately 25% of AML cases. Consequently, FLT3 inhibitors (FLT3i) have a good initial clinical...
Published: 10/28/2024   |   Inventor(s): Jian-kang Jiang, Craig Thomas
Keywords(s): FTL3/IRAK, Inhibitors, MOLECULE, Small, VCXXXX, WIXXXX, WKXXXX, XEXXXX
Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Application > Research Materials
Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties
This technology includes a series of imidazo[1,2-b]pyridazines that display potent inhibition of FLT3, as well as potent binding and activity against FLT3 tyrosine kinase domain and gatekeeper mutations. This chemotype exhibits superior anti-leukemic activity against the common clinically-relevant FLT3-mutant acute myeloid leukemia (AML) in vitro and...
Published: 10/28/2024   |   Inventor(s): Scott Hoyt, Patrick Sutter, Chris Finocchio, Daniel Starczynowski, Gregory Tawa, Craig Thomas
Keywords(s): 2-b]pyridazines, ANTICANCER, Discovery, Imidazo[1, PROPERTIES, VCXXXX, WIXXXX, WKXXXX
Category(s): Application > Therapeutics, Application > Research Materials, TherapeuticArea > Oncology
Use of the Ketamine Metabolite (R,6R)-hydroxynorketamine in Depression
This technology includes the identification and use of a ketamine metabolite, (2R,6R)-2-amino-2-(2-chlorophenyl)-6-hydroxycyclohexanone (HNK), for the treatment of depression. Ketamine is an NMDA receptor antagonist that exerts a rapid and sustained antidepressant and anti-suicidal effect. However, even low doses of ketamine has addictive and psychomimetic...
Published: 10/28/2024   |   Inventor(s): Todd Gould, Irving Wainer, Carlos Zarate, Ruin Moaddel, Patrick Morris, Panos Zanos, Craig Thomas
Keywords(s): 2R, 6R-hydroxynorketamine, depression, Ketamine, METABOLITE, VEXXXX, VNXXXX, WIXXXX, WKXXXX
Category(s): TherapeuticArea > Neurology, TherapeuticArea > Psychiatry/Mental Health, Application > Therapeutics, Application > Research Materials
Pyruvate Kinase M2 Activators for the Treatment of Cancer
This technology describes a series of small-molecule activators of the pyruvate kinase M2 isoform (PK-M2). Pyruvate kinase (PK) is a critical metabolic enzyme that catalyzes the last step of the glycolytic pathway. It exists in several isoforms with different patterns of tissue expression. One isoform, PK-M2, is expressed in cells with a high rate...
Published: 11/5/2024   |   Inventor(s): Jian-kang Jiang, Matthew Boxer, Min Shen, Douglas Auld, Craig Thomas
Keywords(s): Activator, ACTIVATORS, CANCER, CBXXXX, CXXXXX, Dimer, IBXXXX, ISOFORM, IXXXXX, M2, METABOLIC, METABOLITE, PK, PKM2, PK-M2, Proliferation, PYRUVATE, pyruvate kinase, small molecule, Tetramer, tumor
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Application > Diagnostics, Application > Research Materials
Pyruvate Kinase M2 Activators for the Treatment of Cancer
NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage...
Published: 10/28/2024   |   Inventor(s): Min Shen, Craig Thomas, Douglas Auld, Matthew Boxer
Keywords(s): [1, [b], 2, 2-oxo-1, 3, 3-oxo-3, 4], 4-dihydroquinoline-2H-benzo, 4-tetrahydroquinoline-6-sulfonamides, ACTIVATORS, CB3CXX, CB3XXX, CBXXXX, CXXXXX, Human, Kinase, MOLECULE, Oxazine-7-sulfonamides, Patent Category - Chemistry, PYRUVATE, Small, Substituted
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology
Caspase Inhibitors Useful for the Study of Autoimmune or Inflammatory Diseases
Novel and potent caspase 1 inhibitors are available for licensing. In particular, this technology discloses potent and selective caspase 1 inhibitors that target the active site of the enzyme. Caspase 1 is known to play a pro-inflammatory role in numerous autoimmune and inflammatory diseases and therefore represents an excellent target for treatment...
Published: 10/28/2024   |   Inventor(s): Matthew Boxer, Craig Thomas
Keywords(s): 1, Amyotrophic lateral sclerosis, Amyotrophic lateral sclerosis 1; Amyotrophic lateral scleros, Amyotrophic lateral sclerosis 6, Caspase, IB3XXX, IBXXXX, Inflammatory bowel disease 1, inhibitor, IXXXXX, Lou Gehrig's disease, Patent Category - Chemistry
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Diagnostics, Application > Research Materials, Application > Therapeutics, TherapeuticArea > Immunology
Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia
NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage...
Published: 10/28/2024   |   Inventor(s): Craig Thomas
Keywords(s): 3-@hydroxyacyl-coa dehydrogenase deficiency, ACTIVATORS, CB3CXX, CB3XXX, CBXXXX, CXXXXX, HAD deficiency, HIS deficiency, Histidinemia, Human, Kinase, MOLECULE, Patent Category - Chemistry, PYRUVATE, Small
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology